« previous next »
Pages: [1]

Author Topic: (Summary) PML risk and Tysabri: The elephant in the room (Lancet)  (Read 167 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9841
  • MS diagnosed 1980
  • Location: Pacific Northwest
(Summary) PML risk and Tysabri: The elephant in the room (Lancet)
« on: October 11, 2017, 10:47:48 am »
From Lancet Neurology, October 11, 2017:

PML risk and natalizumab: The elephant in the room
Report to moderator   Logged
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.
Pages: [1]
« previous next »
 

Related Topics

  Subject / Started by Replies Last post
0 Replies
75 Views 		Last post June 20, 2016, 05:55:11 pm
by agate
0 Replies
154 Views 		Last post September 28, 2016, 04:53:58 pm
by agate
5 Replies
235 Views 		Last post June 05, 2022, 04:37:54 pm
by agate
0 Replies
26 Views 		Last post September 02, 2022, 09:39:32 pm
by agate
0 Replies
1435 Views 		Last post November 24, 2023, 09:14:23 pm
by agate